TSVC — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Jasper Therapeuticsjaspertherapeutics.com inNASDAQ: JSPRSeries A · Jul 2026 · $14M

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.

BiotechHealthtechRedwood City, US

Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)

Co-investorsAvego BioScience Capital Qiming Venture Partners USA Roche Venture Fund Abingworth Ikarian Capital

Dexmatedexmate.ai in 𝕏Feb 2026

DexMate develops physical AI technology, providing products intended to support the building of embodied AI and robotics systems.

AI & Machine LearningHardwareRoboticsSanta Clara, US

Yuzhe Qin(Founder)Tao Chen(Founder)Chongyang Wang(Founder)Wenda Wang(Founder)

Co-investorsLG Technology Ventures Mana Ventures Sinovel Angel WestWave Capital Cadenza

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.